The coronavirus pandemic currently shocking the world gained entry into Nigeria with its first case confirmed on the 27th of February, 2020 in Lagos state. The discovery spiralled into a frenzy of misinformation as the NCDC and Federal Ministry of Health worked to allay citizens’ fears and contain the outbreak. It is important that we all play a role in beating the virus by sharing only validated information and promoting effective preventive measures.

The Coronavirus CivActs Campaign (CCC) gathers rumours, concerns and questions from communities across Nigeria to eliminate information gaps between the government, media, NGOs and citizens. By providing the public with facts, the CCC ensures a better understanding of needs regarding the coronavirus and debunks rumours before they can do more harm. Information sharing will be critical to defeating the virus, due to the diverse cultural backgrounds and drawbacks in national education.

Coronavirus poses a serious threat to Nigeria's population of over 180 million people given the country's weak healthcare system, high level of poverty, crowded living conditions and deep-set corruption in government. Economic and insecurity conditions in Nigeria were already tenuous before this outbreak, and Nigeria already fares badly against any health indicators, with high mortality rates and poor life expectancy. When and if coronavirus hits the highly populated communities of Nigeria's cities, it could be a disaster.

It is absolutely critical that Nigeria deals with this pandemic in forward-thinking, open, transparent ways to ensure the well-being of citizens, build resilience and rapidly curb the potential for social conflict. In Nigeria, this is a huge challenge but also a real opportunity to reimagine public health systems, redefine the relationship between citizens and those in power, and reinvigorate governance.

New developments in the COVID-19 response in Nigeria

Here is a breakdown of some of the major developments in the COVID-19 response as of September 1, 2020 based on the announcements of the Presidential Task Force on COVID-19 and the Nigeria Center for Disease Control (NCDC) and the Federal Ministry of Health:

- The COVID-19 case fatality rate has dropped slightly to 1.88%. This has been attributed to an improvement of treatment methods.
- The new epicentre of the virus in Nigeria is Plateau state. Other states that have been epicentres for the virus in the past are Kano, Lagos, Ogun and Akwa Ibom.
- Resumption of international flights has been rescheduled for the 5th of September, 2020.
- 14 private laboratories have been accredited for COVID-19 testing in Nigeria; 11 in Lagos and 1 each in FCT, Rivers and Imo.
- 9 out of 36 states in Nigeria have published their COVID-19 expenditure so far, these include Lagos, Ogun, Ondo, Ekiti, Oyo, Kwara, Kaduna, Katsina and Ebonyi.

Lagos State Reduces Isolation Centres:
Due to a decrease in the number of COVID-19 positive cases, the Lagos state government on August 2nd 2020 announced the shutdown of the Eti-Osa Isolation Centre and the Agidingbi Isolation
The NCDC has accredited 14 laboratories in Nigeria for COVID-19 testing. These laboratories are:

<table>
<thead>
<tr>
<th>S/N</th>
<th>Name of Laboratory</th>
<th>State</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Total Medical Services</td>
<td>Lagos</td>
<td>Total towers, Victoria island</td>
</tr>
<tr>
<td>2</td>
<td>SYNLAB</td>
<td>Lagos</td>
<td>9/11 Egbeiyemi Street, Off Coker Road, Ilupeju; +234 700 728 42273</td>
</tr>
<tr>
<td>3</td>
<td>54gene</td>
<td>Lagos</td>
<td>+234 700 342 467 363</td>
</tr>
<tr>
<td>4</td>
<td>Medbury Medical Services</td>
<td>Lagos</td>
<td>7B Admiralty way, Lekki phase 1; 234 907 036 6247</td>
</tr>
<tr>
<td>5</td>
<td>Biologix Medical Services</td>
<td>Lagos</td>
<td>+234 806 958 3073</td>
</tr>
<tr>
<td>6</td>
<td>O2 Medical Services</td>
<td>Lagos</td>
<td>No 7, General Hospital Rd, Gbagada Lagos; +234 811 904 5519</td>
</tr>
<tr>
<td>7</td>
<td>Clina-Lancet Laboratories</td>
<td>Lagos</td>
<td>No 3, Babatunde Jose street, off Adetokunbo Ademola street, Victoria Island; +234 170013 10 399</td>
</tr>
<tr>
<td>8</td>
<td>Clinix Healthcare</td>
<td>Lagos</td>
<td>12, Alhaji Adejumoh Avenue, off Gbagada Oshodi expressway, Anthony; +234 706 618 358</td>
</tr>
<tr>
<td>9</td>
<td>Afriglobal Medicare</td>
<td>Lagos</td>
<td>8 Mobolaji Bank-Anthony way by unity bustop, Ikeja;</td>
</tr>
<tr>
<td>10</td>
<td>Reddington Zaine Laboratory</td>
<td>Lagos</td>
<td>6B, Bendel close, off Bishop Aboyade street, Victoria Island</td>
</tr>
<tr>
<td>11</td>
<td>VCare Diagnostics Limited</td>
<td>Lagos</td>
<td>100, Adetokunbo Ademola, Victoria Island; +234 70 806 31400</td>
</tr>
<tr>
<td>12</td>
<td>eHA Clinics</td>
<td>FCT</td>
<td>Plot 944, Asa and Dantata Street, off Olu Awotesu street</td>
</tr>
<tr>
<td>13</td>
<td>RNZ Laboratory</td>
<td>Rivers</td>
<td><a href="mailto:info@rnzglobal.com">info@rnzglobal.com</a></td>
</tr>
<tr>
<td>14</td>
<td>Everight Laboratory</td>
<td>Imo</td>
<td>Shop 7, Owerri Mall, Egbo road, Owerri; +234 906 630 6001</td>
</tr>
</tbody>
</table>
Herd Immunity is the best way to fight COVID-19

Herd Immunity means that enough people have recovered from the virus so that they cannot infect others or get sick again. In order for that to work, 50-70% of the world population needs to get infected and then develop antibodies. The death toll of such a strategy would be quite large and it is not yet known how long immunity lasts.

COVID-19 is only spread by a few people called ‘super-spreaders’

Anyone can spread the coronavirus. On average, the carrier of the infection infects two or three people with the virus. Those that infect more than the average usually do so because they come into contact with a large number of people.

Good nutrition can prevent the coronavirus

People cannot prevent coronavirus infection through diet. However, a healthy life-style including balanced diet has a positive significance in maintaining an immune system against virus attack.

Healthy young people don’t get sick of COVID-19

Young, healthy people can and do get seriously ill with COVID-19. A person's bodily response to the coronavirus depends on their individual immune system, the amount of virus that infects them, genetic predisposition among other factors.

COVID-19 numbers are skewed to control the masses

Unfortunately, many media channels are presenting a bleaker picture of the situation and feeding into conspiracy theories. However, rates of infection and mortality depend on mass testing figures which do not happen in most places and are sometimes prone to human error.

COVID-19 Vaccines in Development

The WHO released a definitive list of COVID-19 vaccines in development on the 28th of August. A total of 33 candidate vaccines are currently in the clinical testing phase, while 143 candidate vaccines are still in preclinical evaluation.
### Coronavirus Update in Nigeria as of Today - 04/09/2020

<table>
<thead>
<tr>
<th>Number of cases</th>
<th>Deaths</th>
<th>Recovered</th>
<th>Tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>54,743</td>
<td>1,051</td>
<td>42,816</td>
<td>420,543</td>
</tr>
</tbody>
</table>

**Vaccine Institute**

1. University of Oxford/AstraZeneca
   - Number of doses: 1
   - Timing of doses: Intramuscular (IM)
   - Route of Administration: Phase 3

2. Sinovac Biological Inc./Beijing Institute of Biotechnology
   - Number of doses: 1
   - Timing of doses: Intramuscular (IM)
   - Route of Administration: Phase 3

3. SinoVac Research Institute
   - Number of doses: 2
   - Timing of doses: 0, 21 days
   - Route of Administration: IM
   - Clinical stage of testing: Phase 3

4. SinoVac
   - Number of doses: 2
   - Timing of doses: 0, 14 days
   - Route of Administration: IM
   - Clinical stage of testing: Phase 3

5. Wuhan Institute of Biological Products
   - Number of doses: 2
   - Timing of doses: 0, 14 or 0, 21 days
   - Route of Administration: IM
   - Clinical stage of testing: Phase 3

6. Beijing Institute of Biological Products
   - Number of doses: 2
   - Timing of doses: 0, 14 or 0, 21 days
   - Route of Administration: IM
   - Clinical stage of testing: Phase 3

7. Moderna
   - Number of doses: 2
   - Timing of doses: 0, 28 days
   - Route of Administration: IM
   - Clinical stage of testing: Phase 3

8. BioNTech/Pfizer
   - Number of doses: 2
   - Timing of doses: 0, 28 days
   - Route of Administration: IM
   - Clinical stage of testing: Phase 3

9. Anhui Zhifei Longcom Pharmaceutical/Institute of Microbiology, Chinese Academy of Sciences
   - Number of doses: 2 or 3
   - Timing of doses: 0, 28 or 0, 28, 56 days
   - Route of Administration: IM
   - Clinical stage of testing: Phase 2

10. Gamaleya
    - Number of doses: 2
    - Timing of doses: 0, 28 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 2

11. Institute of Medical Biology, Chinese Academy of Medical Sciences
    - Number of doses: 2
    - Timing of doses: 0, 28 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

12. Research Institute for Biological Safety Problems, Rep. of Kazakhstan
    - Number of doses: 2
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

13. Novavax, Pharmaceutical/International
    - Number of doses: 2
    - Timing of doses: Intradermal (ID)
    - Route of Administration: Phase 1 / 2

14. Osaka University/Teijin/Tokara Bio
    - Number of doses: 2
    - Timing of doses: 0, 14 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

15. Cadila Healthcare Limited
    - Number of doses: 3
    - Timing of doses: 0, 28, 56 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

16. Serumab Consortium
    - Number of doses: 2
    - Timing of doses: 0, 28 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

17. Bharat Biotech
    - Number of doses: 2
    - Timing of doses: 0, 14 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

18. Janssen Pharmaceutical Companies
    - Number of doses: 2
    - Timing of doses: 0, 56 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

19. Hikma
    - Number of doses: 2
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

20. Kentek Bioprocessing, Inc.
    - Number of doses: 2
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

    - Number of doses: 2
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1 / 2

22. CDPHER/LEUKOCARE/Universite de Liege
    - Number of doses: 1
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

23. Clever Biopharmaceuticals Inc./GSK/Novavax
    - Number of doses: 2
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

24. Vaxxcel
    - Number of doses: 1
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

25. University of Queensland/CISL/Sequibis
    - Number of doses: 2
    - Timing of doses: 0, 28 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

26. Medigen Vaccine Biologics Corporation/NIAID/NIAMS/Novavax
    - Number of doses: 2
    - Timing of doses: 0, 28 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

27. Instituto Finlay de Virologia, Cuba
    - Number of doses: 2
    - Timing of doses: 0, 28 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

28. FHI360/CSIR/VB Vектор, Rospotrebnadzor, Novavax
    - Number of doses: 2
    - Timing of doses: 0, 21 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

29. West China Hospital, Sichuan University
    - Number of doses: 2
    - Timing of doses: 0, 28 days
    - Route of Administration: IM
    - Clinical stage of testing: Phase 1

---

**Additional Note:**

- **CONFIRMED CASES:** 54,743
- **DEATHS:** 1,051
- **RECOVERED:** 42,816
- **TESTED:** 420,543